Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A domestic Phase 3 multicenter, single-arm, open-label study evaluating the safety and immunogenicity of Tycovac aqueous suspension intramuscular injection in healthy Japanese adults aged 16 years and older and Japanese children aged 1 year to 16 years

Next Previous
Search
Trial Profile

A domestic Phase 3 multicenter, single-arm, open-label study evaluating the safety and immunogenicity of Tycovac aqueous suspension intramuscular injection in healthy Japanese adults aged 16 years and older and Japanese children aged 1 year to 16 years

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tick-borne encephalitis vaccine (Primary)
  • Indications Encephalitis virus infections
  • Focus Therapeutic Use

    • Most Recent Events

    • 04 Apr 2024 New trial record
    • 26 Mar 2024 According to Pfizer media release, the company has applied for manufacturing and sales approval for this drug to the Ministry of Health, Labor and Welfare in March 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top